US EditionEntrada receives authorization to start exon 44 skipping trial in Europe
Summary by CureDuchenne
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Entrada receives authorization to start exon 44 skipping trial in Europe
CureDuchenne provided early funding to Entrada Therapeutics. Entrada has received regulatory authorization in Europe to initiate a Phase 1/2 clinical trial of ENTR-601-44 in ambulatory individuals with Duchenne amenable to skipping exon 44. The study, which will run in the UK and the EU, will start in the 2nd quarter of 2025. Entrada is also planning a Phase 1/2 for ambulatory individuals with Duchenne amenable to skipping exon 45, which will…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
